ImpriMed
ImpriMed is an AI-driven precision medicine company that uses proprietary live-cell drug sensitivity testing and multimodal machine learning to predict anticancer drug responses for canine and feline lymphoma and leukemia, serving 300+ veterinary oncologists across 340+ hospitals while expanding into pharmaceutical CRO services and human oncology.
- Company typePrivate
- Founded2017
- HeadquartersMountain View, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What ImpriMed does
ImpriMed, Inc. is a privately held, AI-driven precision medicine company headquartered in Palo Alto, California, with a regional presence in Seoul, South Korea through ImpriMed Korea. Founded in 2017, the company combines a proprietary robotic ex vivo live-cell drug sensitivity assay with multimodal machine learning models trained on a 2,500+ canine patient outcomes database to predict response to 13 anticancer drugs and CHOP combination therapy for canine and feline lymphoma and leukemia. Its veterinary product portfolio is anchored by the Personalized Prediction Profile (PPP) flagship service and includes a la carte offerings — Drug Response Predictions, Immunoprofile, Flow Cytometry, PARR clonality testing, MDR1 genotyping, and digital cytology — with parallel feline-specific variants. Services are delivered in 3-7 days through an A2LA-accredited US lab (Certificate #5664.01), a proprietary Vet Portal, and FedEx overnight shipping with proprietary transport media.
The company operates three business lines: (1) per-test veterinary service fees to 300+ veterinary oncologists across 340+ collaborating hospitals (primarily US, with Korea via ImpriMed Korea), with quote-based pricing not publicly disclosed; (2) ex vivo CRO services for pharmaceutical and biotech customers, sold via a proposal-based enterprise motion for studies in AML, multiple myeloma, pancreatic cancer, and non-Hodgkin lymphoma; and (3) human precision medicine, planned for 2026 launch on the xCellSense platform as a research/investigational-use predictive service for human hematologic cancers. Revenue mechanics blend per-test transactional fees, multi-year CRO contracts, and a planned professional services stream in human oncology.
ImpriMed has raised approximately $34.7 million across five funding rounds (most recently a $23 million Series A in November 2023 led by SBVA) and operates with 11-50 employees. Recent strategic moves include the appointment of a Chief Commercial Officer in October 2025, relocation to a new Palo Alto laboratory, and selection for an oral presentation at the 2025 American Society of Hematology Annual Meeting. The company's academic and ecosystem footprint includes 17 peer-reviewed publications, Mayo Clinic Platform AI Accelerator alumni status, and ongoing conference presence at ASH, ASCO, VCS, ACVIM, and AACR.
ImpriMed firmographics
Firmographics- Name
- ImpriMed
- Legal name
- ImpriMed, Inc.
- Website
- https://imprimedicine.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ImpriMed is an AI-driven precision medicine company that uses proprietary live-cell drug sensitivity testing and multimodal machine learning to predict anticancer drug responses for canine and feline lymphoma and leukemia, serving 300+ veterinary oncologists across 340+ hospitals while expanding into pharmaceutical CRO services and human oncology.
- Ownership category
- akta.pro rank
ImpriMed industry classification
Industry- Product category
- Veterinary Diagnostics
- NAICS
- Veterinary Services (54194), Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Reference Laboratory Testing (Clinical Pathology & Chemistry) (HLAMADAA)
- akta.pro secondary industry
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)
Keywords
Where ImpriMed is headquartered
LocationHeadquarters
- HQ city
- Mountain View
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
ImpriMed business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure, Others
Revenue model
- Per-test veterinary service fees: Per-order service fees for canine and feline diagnostic and predictive services: Personalized Prediction Profile (PPP), Drug Response Predictions, Immunoprofile, Flow Cytometry only, PARR only, MDR1 genotyping, and cytology; prices are quote-based and not publicly disclosed, with services ordered through the Vet Portal after vet onboarding.
- Ex vivo CRO services for pharma and biotech: Contract research / professional services revenue from pharmaceutical and biotech customers using ImpriMed's live-cell-based predictive analytics to accelerate oncology pipelines (e.g., AML, multiple myeloma, pancreatic cancer, non-Hodgkin lymphoma); engagements initiated via a Request a Proposal flow.
- Human precision medicine research services: Planned expansion into human precision medicine by 2026, offering research and investigational-use predictive services for AML and other hematologic malignancies using the xCellSense platform (revenue model currently research/collaboration-oriented, not yet a commercial diagnostic).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Per-order veterinary service fees (quote-based) |
| Other | Multi-year contract | CRO services for pharma (proposal-based) |
Go-to-market motion4 records
Distribution channels4 records
Marketing channels8 records
ImpriMed product offering
Product offeringCore offering
ImpriMed provides AI-driven precision medicine services that predict anticancer drug response for individual veterinary and human oncology patients. Its core offering is a laboratory-based diagnostic and predictive service (centered on the Personalized Prediction Profile) that combines live-cell drug sensitivity testing, flow cytometry, and PARR clonality testing with proprietary multimodal AI models trained on thousands of real-world canine patient outcomes. The company also sells contract research services (Ex Vivo CRO Services for Pharma) using its xCellSense platform to accelerate pharmaceutical oncology pipelines.
Product overview
ImpriMed offers a single integrated AI-driven precision medicine platform with distinct service lines for veterinary (canine and feline), human oncology, and pharmaceutical CRO use. The veterinary offering is built around the Personalized Prediction Profile (PPP) flagship service, which combines live-cell drug sensitivity testing, flow cytometry, PARR clonality testing, and proprietary AI models trained on 2,500+ canine patient outcomes to predict response to 13 anticancer drugs and CHOP combination therapy. Supporting modules — Drug Response Predictions, Immunoprofile, Flow Cytometry, PARR, MDR1 Genotyping, and Digital Cytology — can be ordered individually or bundled within the PPP, with parallel feline-specific variants of Immunoprofile, Flow Cytometry, and PARR. The xCellSense platform extends the same ex vivo drug sensitivity testing approach to human hematologic cancers (AML, ALL, multiple myeloma, non-Hodgkin lymphoma). The Ex Vivo CRO Services for Pharma arm offers live-cell-based analytics to pharmaceutical companies to accelerate oncology pipelines, and the Veterinary Cancer Pioneers Podcast serves as a brand content channel.
Differentiator
Problem solved
Functional benefit
Brands
- xCellSense platform: ImpriMed's proprietary platform used for ex vivo drug sensitivity testing combined with genomic profiling to predict clinical responses and identify synergistic drug combinations in oncology research, including acute myeloid leukemia.
Products and services
- Personalized Prediction Profile (PPP) AI-driven drug response prediction service for canine lymphoma and leukemia that combines live-cell drug sensitivity testing, flow cytometry, and PARR clonality testing with proprietary AI models to predict response to 13 anticancer drugs and CHOP combination therapy. For board-certified veterinary oncologists and their canine patients, with 7-day turnaround.
- Drug Response Predictions Standalone AI-driven anticancer drug selection service for canine patients using ImpriMed's live-cell drug sensitivity testing platform, providing personalized drug response predictions without the full Immunoprofile component. For veterinary oncologists.
- Canine Immunoprofile Canine diagnostic support service combining flow cytometry and PARR testing to subtype lymphoma/leukemia and provide prognostic information. For veterinary oncologists.
- Canine Flow Cytometry Canine flow cytometry service that determines lymphoma or leukemia subtypes by quantifying levels of 10 antigens (CD21, CD79a, CD3, CD4, CD8, CD5, CD45, CD34, CD14, MHC class II) on patient tumor cells. For veterinary oncologists.
- Canine PARR (PCR for Antigen Receptor Rearrangement) Canine PCR-based clonality test that detects neoplastic B-cell or T-cell clones by amplifying the VJ region of the immunoglobulin heavy chain gene and a region in the T-cell receptor gamma chain gene, helping discriminate lymphoma from reactive or inflammatory conditions. For veterinary oncologists.
- Multidrug Sensitivity Genotyping (MDR1) Canine genetic test that identifies MDR1 carrier status to predict drug sensitivity and help avoid adverse drug reactions. For veterinary oncologists.
- Digital Cytology Cytology confirmation service for lymphoma or leukemia diagnosis with digital analysis. For veterinary oncologists.
- Feline Immunoprofile Feline-specific diagnostic support service combining PARR and flow cytometry for lymphoma/leukemia subtype diagnosis, including cell-sizing data for high-accuracy feline lymphoma characterization. For veterinary oncologists treating feline patients.
- Feline Flow Cytometry Feline-specific flow cytometry service for accurate lymphoma or leukemia subtype determination. For veterinary oncologists treating feline patients.
- Feline PARR Feline-specific PCR for Antigen Receptor Rearrangement assay with high-specificity detection of clonal neoplasia and B-cell/T-cell clonality testing, returning cell sizing and immunophenotyping results in 3-4 calendar days. For veterinary oncologists treating feline patients.
- Ex Vivo CRO Services for Pharma Contract research organization service offering live-cell-based predictive analytics to accelerate pharmaceutical and biotech oncology pipelines, with ex vivo drug sensitivity testing on patient-derived cancer cells across programs such as AML, multiple myeloma, pancreatic cancer, and non-Hodgkin lymphoma. For pharmaceutical and biotechnology companies.
- Human Precision Medicine (xCellSense Platform) AI-driven precision medicine service for human oncology that uses the xCellSense platform to combine ex vivo drug sensitivity testing with genomic profiling to predict patient-specific drug responses and identify synergistic drug combinations, with research and investigational use in AML, ALL, multiple myeloma, and non-Hodgkin lymphoma. For academic translational researchers, hematologist-oncologists, and pharmaceutical partners.
Companies that use ImpriMed
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
ImpriMed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability6 records
ImpriMed partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship and core.
- Mayo Clinic PlatformflagshipImpriMed was one of 7 startups selected for the Mayo Clinic AI Accelerator (per MedCity News 2022 coverage referenced on ImpriMed's homepage). The accelerator supports validation and scaling of ImpriMed's AI platform in a clinical environment.
- Stripe, Inc.coreStripe is ImpriMed's third-party payment processor for veterinary clinic transactions; ImpriMed does not store any card payment data, and all Stripe-collected data is subject to Stripe's privacy notice.
- FedExcoreImpriMed provides prepaid FedEx shipping labels and boxes to veterinary clinics to enable overnight delivery of live tumor and blood samples to its Palo Alto lab; central to the live-cell assay workflow.
- American Association for Laboratory Accreditation (A2LA)coreA2LA accredits ImpriMed's US laboratory under Certificate #5664.01 for canine lymphoma/leukemia PARR clonality testing, flow cytometry immunophenotyping, MDR1 genotyping, and feline PARR/flow cytometry services.
Scale indicators13 records
Recent moves9 records
Expansion highlights6 records
ImpriMed competitors and assessment
Company assessmentDirect peers
- FidoCure (One Health Company): FidoCure offers precision medicine and genetic testing for canine cancer, directly overlapping ImpriMed's veterinary oncology positioning. Both companies target veterinary oncologists with AI-driven drug selection tools for dogs with cancer.
- Vidium Animal Health: Vidium provides precision medicine diagnostics and genomic testing for veterinary cancer patients. It is a direct competitor in the veterinary oncology precision diagnostics space, serving the same board-certified oncologist customer base as ImpriMed.
Emerging players
- PetDx: PetDx develops liquid biopsy and multi-cancer early detection tests for dogs using next-generation sequencing. While focused on detection rather than drug response prediction, it competes for the same veterinary oncology budget and clinical workflow slot as ImpriMed.
- Personalis: Personalis provides genomics-based precision oncology services for biopharma and clinicians, with a focus on minimal residual disease and tumor profiling. Comparable to ImpriMed's pharma CRO arm and its planned human oncology expansion via multi-omic AI.
- Notable Labs: Notable Labs offers ex vivo drug sensitivity testing for cancer patients using automated platforms to predict treatment response. It is a direct comparable to ImpriMed's ex vivo CRO offering and xCellSense platform, especially in hematologic malignancies.
- Embark Veterinary: Embark provides dog DNA and genetic health testing, including MDR1 and breed-related risk screening. It overlaps with ImpriMed's MDR1 genotyping and precision veterinary positioning but targets a broader pet-owner consumer audience.
Broad incumbents
- IDEXX Laboratories: IDEXX is the dominant veterinary diagnostics company, offering reference lab services across many species and analytes. It is a broad incumbent whose reference lab and specialty offerings overlap with ImpriMed's veterinary diagnostic services, though IDEXX does not focus specifically on AI-driven oncology drug response prediction.
- Antech Diagnostics (Mars Petcare): Antech is a large veterinary reference laboratory network owned by Mars Petcare, offering broad diagnostic panels including oncology. It competes with ImpriMed for veterinary clinic reference lab spend, though its AI-driven lymphoma drug response prediction capability is not a comparable focus.
- Tempus AI: Tempus is a leading human precision medicine company using AI and multi-modal data (genomics, imaging, clinical) to support oncology decision-making. It is relevant as ImpriMed's reference point for scaling its xCellSense human precision medicine platform.
- Guardant Health: Guardant Health is a leading liquid biopsy and precision oncology company focused on human cancer. It is a broad incumbent relevant to ImpriMed's human oncology roadmap, particularly as a comparator on data scale and pharma partnership economics.
Market position
Strengths5 records
Weaknesses2 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
ImpriMed social profiles
Digital presenceImpriMed compliance and trust
Trust signalCompliance5 records
ImpriMed financial estimates
Financial estimateRevenue estimate
Valuation estimate
ImpriMed leadership team
Management profileNumber of profiles
Profiles3 records
ImpriMed subsidiaries and ownership
Company hierarchySubsidiaries1 record
ImpriMed funding detail
Funding detailFunding overview
Funding rounds6 records
Investors29 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ImpriMed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ImpriMed
What does ImpriMed do?
ImpriMed provides AI-driven precision medicine services that predict anticancer drug response for individual veterinary and human oncology patients. Its core offering is a laboratory-based diagnostic and predictive service (centered on the Personalized Prediction Profile) that combines live-cell drug sensitivity testing, flow cytometry, and PARR clonality testing with proprietary multimodal AI models trained on thousands of real-world canine patient outcomes. The company also sells contract research services (Ex Vivo CRO Services for Pharma) using its xCellSense platform to accelerate pharmaceutical oncology pipelines.
Is ImpriMed a public or private company?
ImpriMed is a private company. It is classified as venture growth investor backed and is currently operating.
When was ImpriMed founded?
ImpriMed was founded in 2017. It employs 11 to 50 people.
Where is ImpriMed based?
ImpriMed is headquartered in Mountain View, United States, in the North America region.
How does ImpriMed make money?
Three revenue lines are on record. Per-test veterinary service fees are the primary driver. The others are ex vivo CRO services for pharma and biotech and human precision medicine research services.
Who are ImpriMed's main competitors?
Direct peers on record are FidoCure (One Health Company) and Vidium Animal Health. Emerging players are PetDx, Personalis, Notable Labs and Embark Veterinary. Broad incumbents are IDEXX Laboratories, Antech Diagnostics (Mars Petcare), Tempus AI and Guardant Health.
Does ImpriMed have an API?
No public API is recorded for ImpriMed.
What industry is ImpriMed in?
ImpriMed's product category is Veterinary Diagnostics. Its primary akta.pro industry code is HLAMADAA, Reference Laboratory Testing (Clinical Pathology & Chemistry), with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 54194 and its SIC code is 8071.